


## DPP-4i treatment doesn't up MI, stroke risk in seniors

February 25 2017



(HealthDay)—For older U.S. Medicare beneficiaries, dipeptidyl



peptidase-4 inhibitors (DPP-4i) treatment is not associated with increased cardiovascular (CV) risk relative to sulfonylureas (SU) and thiazolidinediones (TZD), according to a study published online Feb. 14 in *Diabetes, Obesity and Metabolism*.

Mugdha Gokhale, Ph.D., from the University of North Carolina at Chapel Hill, and colleagues identified two new-user cohorts of Medicare beneficiaries aged >65 years: DPP-4i versus SU (30,130 and 68,382 initiators, respectively) and DPP-4i versus TZD (20,596 and 13,526, respectively) during 2007 to 2013.

The researchers found that the hazard ratio for the composite outcome (myocardial infarction [MI], stroke, and all-cause mortality) was 0.75 (95 percent confidence interval [CI], 0.72 to 0.79) in the DPP-4i versus SU comparison. For DPP-4i and SU, respectively, the one-year risks for MI were 1.00 (95 percent CI, 0.89 to 1.12) and 1.47 (95 percent CI, 1.38 to 1.56) per 100 patients; the corresponding numbers for stroke risk were 0.98 (95 percent CI, 0.87 to 1.10) and 1.09 (95 percent CI, 1.01 to 1.17). For DPP-4i versus TZD, the hazard ratio for the composite outcome was 0.94 (95 percent CI, 0.86 to 1.02). The one-year risks for MI and stroke were about 0.90 and 0.80, respectively, per 100 patients for both DPP-4i and TZD.

"Though limited by the short treatment duration, our study suggests no increased short-term risk of MI <u>stroke</u> or heart failure with DPP-4i versus SU/TZD," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

**More information:** Abstract

Full Text (subscription or payment may be required)



Copyright © 2017 <u>HealthDay</u>. All rights reserved.



Citation: DPP-4i treatment doesn't up MI, stroke risk in seniors (2017, February 25) retrieved 20 February 2023 from <a href="https://medicalxpress.com/news/2017-02-dpp-4i-treatment-doesnt-mi-seniors.html">https://medicalxpress.com/news/2017-02-dpp-4i-treatment-doesnt-mi-seniors.html</a>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.